Naive-like T cell composition in CAR T products predicts durable lymphoma response
Start here
A multicenter, multi-trial cohort study of patients with non-Hodgkin lymphoma has identified a correlate of durable benefit from anti-CD19 CAR T cell therapy. A higher proportion of naive-like and stem cell memory-like CCR7+CD45RA+ T cells in the pre-infusion CAR T product was associated with durable clinical benefit. The finding was validated in an independent external cohort that included different CAR T products, suggesting the marker may generalize across manufacturing approaches. The analysis was published online in Nature Medicine on 23 October 2026 (DOI: 10.1038/s41591-026-04707-w). Open questions include how the association can be applied in product release decisions and whether enriching for these T cell subsets improves outcomes prospectively.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- nature.comPickDeterminants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma
A multicenter, multi-trial cohort analysis of non-Hodgkin lymphoma found that a higher proportion of naive-like and stem cell memory-like CCR7+CD45RA+ T cells in the pre-infusion CAR T product was associated with durable clinical benefit from anti-CD19 CAR T therapy. The association was validated in an independent external cohort including different CAR T products. The paper was published online on 23 October 2026, DOI:10.1038/s41591-026-04707-w.
Heat trend for this story
Heat now 7·Peak in the comparable set 10 (Oct 23 08:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.